US Patent

US11013703 — Sotalol compositions and uses of the same

Formulation · Assigned to Arbor Pharmaceuticals LLC · Expires 2034-04-01 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects oral solutions containing sotalol hydrochloride that are stable and do not require swallowing.

USPTO Abstract

The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Drugs covered by this patent

Patent Metadata

Patent number
US11013703
Jurisdiction
US
Classification
Formulation
Expires
2034-04-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Arbor Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.